DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight, 2022,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including Diffuse Large B-Cell Lymphoma clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Diffuse Large B-Cell Lymphoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Diffuse Large B-Cell Lymphoma NDA approvals (if any), and product development activities comprising the technology, Diffuse Large B-Cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.
Key takeaways from the Diffuse Large B-Cell Lymphoma Pipeline
- DelveInsight’s Diffuse Large B-Cell Lymphoma Pipeline analysis depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Diffuse Large B-Cell Lymphoma treatment.
- The leading Diffuse Large B-Cell Lymphoma Companies are working such as Genmab, Roche, Acerta Pharma, Autolus, Xynomic Pharmaceuticals, Genentech, Celgene, AbbVie, Mabion, Pharmacyclics LLC., Shanghai Yingli Pharmaceutical, Philogen, Amgen, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., JW Therapeutics, Incyte Corporation, BeiGene, Miltenyi Biotec GmbH, Beijing InnoCare Pharma Tech Co., Ltd., Bristol-Myers Squibb, Celleron Therapeutics, Otsuka Pharmaceutical, Curis, Inc., Bayer, Kartos Therapeutics, Inc., Shanghai Institute Of Biological Products, Novartis Pharmaceuticals, Constellation Pharmaceuticals, Secura Bio, Inc., CytomX Therapeutics, Juno Therapeutics, Teneobio, Inc., Telios Pharma, Inc., Sorrento Therapeutics, Inc., Curocell Inc., TG Therapeutics, Inc., Tessa Therapeutics, TCR2 Therapeutics, Plexxikon, Shattuck Labs, Inc., MEI Pharma, Inc., Boryung Pharmaceutical Co., Ltd, Sutro Biopharma, Inc, Newave Pharmaceutical Inc, Eden BioCell Ltd., Adicet Bio, Inc, VelosBio Inc., Seagen Inc., Eisai Co Ltd, Nurix Therapeutics, Inc., Prelude Therapeutics, Xencor, and others.
- Promising Diffuse Large B-Cell Lymphoma Pipeline therapies such as Rituximab (RTX), Tafasitamab, Bendamustine (BEN), KTE-C19, Atezolizumab, Cyclophosphamide, Fludarabine, Ibrutinib, DA-EPOCH-R, Lenalidomide, VELCADE, Cyclophosphamide, HS006+CHOP, and others.
- The Diffuse Large B-Cell Lymphoma Companies and academics are working to assess challenges and seek opportunities that could influence Diffuse Large B-Cell Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Diffuse Large B-Cell Lymphoma.
To explore more information on the latest breakthroughs in the Diffuse Large B-Cell Lymphoma Pipeline treatment landscape of the report, click here @ Diffuse Large B-Cell Lymphoma Pipeline Outlook
Diffuse Large B-Cell Lymphoma Overview
Diffuse Large B-Cell Lymphoma (DLBCL) is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections. When you have a lymphoma, the abnormal lymphocytes build up in lymph nodes or other body organs. Each year about 5,500 people are diagnosed with DLBCL. This makes up about 40 out of 100 cases (40%) of NHL in adults. DLBCL is more common in males than females. Most people with DLBCL first notice painless lumps, often in their neck, armpit or groin. These are swollen (enlarged) lymph nodes. They usually grow quite quickly, over just a few weeks. Sometimes, DLBCL can develop in lymph nodes deep inside your body where they can’t be felt from the outside. The swollen nodes can form large lumps – known as ‘bulky disease’. DLBCL can also develop outside lymph nodes, called ‘extranodal’ disease. This affects around 1 in 5 people with DLBCL.
Recent Developmental Activities in the Diffuse Large B-Cell Lymphoma Pipeline
- Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab’s proprietary DuoBody technology. Genmab’s DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T cell mediated killing of lymphoma B cells. CD20 is a clinically validated therapeutic target, and is expressed on many B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies’ broad oncology collaboration. Currently, it is in phase 3 stage of development for the treatment of Diffuse Large B-Cell Lymphoma.
- Glofitamab is an investigational CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B-cells and CD3 on the surface of T-cells. This dual targeting activates and redirects a patient’s existing T-cells to engage and eliminate target B-cells by releasing cytotoxic proteins into the B-cells. Glofitamab is based on a novel structural format which we call ‘2:1’, which refers to the structure of the antibody. It is engineered to have two ‘Fab’ regions which bind to CD20, and one ‘Fab’ region which binds to CD3. A robust clinical development programme for glofitamab is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with CD20-positive B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and follicular lymphoma, and other blood cancers.
- Acalabrutinib is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.
- AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for single target activity. By simultaneously targeting two B cell antigens, AUTO3 is designed to minimize relapse due to single antigen loss in patients with B cell malignancies. AUTO3 is currently in phase I/II stage of development for the treatment of Diffuse Large B-Cell Lymphoma.
- Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, it is in phase 2 stage of development for the treatment of Diffuse Large B-Cell Lymphoma.
Request a sample and discover the recent advances in Diffuse Large B-Cell Lymphoma Ongoing Clinical Trial Analysis and Medications, click here @ Diffuse Large B-Cell Lymphoma Treatment Landscape
Diffuse Large B-Cell Lymphoma Emerging Drugs
- Epcoritamab: Genmab
- Glofitamab: Roche
- Acalabrutinib: Acerta Pharma
- AUTO 3: Autolus
- Abexinostat: Xynomic Pharmaceuticals
Diffuse Large B-Cell Lymphoma Pipeline Therapeutics Analysis
There are approx. 80+ key companies which are developing the therapies for Diffuse Large B-Cell Lymphoma. The companies which have their Diffuse Large B-Cell Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Genmab.
For further information, refer to the detailed Diffuse Large B-Cell Lymphoma Unmet Needs, Diffuse Large B-Cell Lymphoma Market Drivers, and Market Barriers, click here for Diffuse Large B-Cell Lymphoma Ongoing Clinical Trial Analysis
Scope of the Diffuse Large B-Cell Lymphoma Pipeline Report
- Coverage- Global
- Diffuse Large B-Cell LymphomaCompanies- Genmab, Roche, Acerta Pharma, Autolus, Xynomic Pharmaceuticals, Genentech, Celgene, AbbVie, Mabion, Pharmacyclics LLC., Shanghai Yingli Pharmaceutical, Philogen, Amgen, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., JW Therapeutics, Incyte Corporation, BeiGene, Miltenyi Biotec GmbH, Beijing InnoCare Pharma Tech Co., Ltd., Bristol-Myers Squibb, Celleron Therapeutics, Otsuka Pharmaceutical, Curis, Inc., Bayer, Kartos Therapeutics, Inc., Shanghai Institute Of Biological Products, Novartis Pharmaceuticals, Constellation Pharmaceuticals, Secura Bio, Inc., CytomX Therapeutics, Juno Therapeutics, Teneobio, Inc., Telios Pharma, Inc., Sorrento Therapeutics, Inc., Curocell Inc., TG Therapeutics, Inc., Tessa Therapeutics, TCR2 Therapeutics, Plexxikon, Shattuck Labs, Inc., MEI Pharma, Inc., Boryung Pharmaceutical Co., Ltd, Sutro Biopharma, Inc, Newave Pharmaceutical Inc, Eden BioCell Ltd., Adicet Bio, Inc, VelosBio Inc., Seagen Inc., Eisai Co Ltd, Nurix Therapeutics, Inc., Prelude Therapeutics, Xencor, and others.
- Diffuse Large B-Cell Lymphoma Pipeline therapies- Rituximab (RTX), Tafasitamab, Bendamustine (BEN), KTE-C19, Atezolizumab, Cyclophosphamide, Fludarabine, Ibrutinib, DA-EPOCH-R, Lenalidomide, VELCADE, Cyclophosphamide, HS006+CHOP, and others
Dive deep into rich insights for drugs for Diffuse Large B-Cell Lymphoma Market Drivers and Diffuse Large B-Cell Lymphoma Market Barriers, click here @ Diffuse Large B-Cell Lymphoma Unmet Needs and Analyst Views
Table of Content
- Introduction
- Diffuse Large B-Cell Lymphoma Executive Summary
- Diffuse Large B-Cell Lymphoma: Overview
- Diffuse Large B-Cell Lymphoma Pipeline Therapeutics
- Diffuse Large B-Cell Lymphoma Therapeutic Assessment
- Diffuse Large B-Cell Lymphoma – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Diffuse Large B-Cell Lymphoma Collaboration Deals
- Late Stage Products (Phase III)
- Epcoritamab: Genmab
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Abexinostat: Xynomic Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- AUTO 3: Autolus
- Drug profiles in the detailed report…..
- Inactive Products
- Diffuse Large B-Cell Lymphoma Key Companies
- Diffuse Large B-Cell Lymphoma Key Products
- Diffuse Large B-Cell Lymphoma- Unmet Needs
- Diffuse Large B-Cell Lymphoma- Market Drivers and Barriers
- Diffuse Large B-Cell Lymphoma- Future Perspectives and Conclusion
- Diffuse Large B-Cell Lymphoma Analyst Views
- Diffuse Large B-Cell Lymphoma Key Companies
- Appendix
Got Queries? Find out the related information on Diffuse Large B-Cell Lymphoma Mergers and acquisitions, Diffuse Large B-Cell Lymphoma licensing activities @ Diffuse Large B-Cell Lymphoma Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services